OS Therapies (NYSE:OSTX) Earns “Buy” Rating from D. Boral Capital

Posted by Doug Wharley on Feb 21st, 2025

D. Boral Capital reiterated their buy rating on shares of OS Therapies (NYSE:OSTX – Free Report) in a research report sent to investors on Thursday,Benzinga reports. D. Boral Capital currently has a $20.00 price objective on the stock.

Separately, Maxim Group raised their price target on shares of OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, January 16th.

Get Our Latest Research Report on OS Therapies

OS Therapies Stock Performance

Shares of OSTX opened at $1.89 on Thursday. OS Therapies has a 12 month low of $1.58 and a 12 month high of $7.00. The company has a 50-day moving average price of $3.31 and a two-hundred day moving average price of $3.14.

Insiders Place Their Bets

In other news, major shareholder Shalom Auerbach sold 16,720 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $6.74, for a total transaction of $112,692.80. Following the completion of the sale, the insider now owns 2,531,211 shares of the company’s stock, valued at approximately $17,060,362.14. This trade represents a 0.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Institutional Trading of OS Therapies

An institutional investor recently raised its position in OS Therapies stock. CM Management LLC raised its position in shares of OS Therapies Inc (NYSE:OSTX – Free Report) by 120.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 110,044 shares of the company’s stock after buying an additional 60,044 shares during the period. CM Management LLC owned about 0.51% of OS Therapies worth $471,000 as of its most recent filing with the Securities and Exchange Commission.

OS Therapies Company Profile

(Get Free Report)

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.